Naturally Splendid (TSXV:NSP) announced an update on the cannabinoid regulatory environment in Canada.
As quoted in the press release:

The recent news that Health Canada is beginning to grant Authorized Licensed Producers under the Marihuana for Medical Purposes Regulations the approval to produce cannabis oil is a significant step forward in the cannabis industry as regulations continue to evolve. This latest development allows patients to have access to new formulations of cannabinoid-infused products, which are viable alternatives to smoke-inhalation.
While NSE remains focused on the industrial hemp industry, this movement creates the opportunity for the company to license formulation technology acquired in an earlier transaction with Full Spectrum Laboratories Limited (FSL), to Licensed Producers and eventually, infused product manufacturers providing the platform to develop unique and innovative cannabinoid-infused products for the medical and recreational marijuana markets.
Naturally Splendid is positioned to capitalize on these emerging markets as in an earlier news release it was reported it’s 100% owned American subsidiary, Naturally Splendid Enterprises USA Limited (“Naturally Splendid USA), had secured a suite of cannabinoid extraction and formulation technologies from FSL.
FSL invested well over $10 million developing the technologies covered in the license with Naturally Splendid USA.
The license grants Naturally Splendid USA worldwide rights to a suite of advanced cannabinoid technologies, including the first issued USPTO patent for water-soluble cannabinoids, essential for the development and manufacturing of cannabinoid-based nutraceutical and pharmaceutical products and therapies. The license allows Naturally Splendid USA to create products and industrial solutions in those countries and jurisdictions that allow for the manufacture and distribution of cannabinoid based products.
The license allows Naturally Splendid USA to sub-license these cannabinoid technologies to approved third party companies in countries that allow for the production and distribution of cannabinoid-based products and solutions.
The current American market for cannabinoid-based products is estimated to exceed $300 million this year and is expected to show significant growth year after year for the foreseeable future as regulations continue to evolve and additional states amend their marijuana and industrial hemp laws.
Naturally Splendid CEO Craig Goodwin states, “We want to maximize revenue opportunities relating to cannabis sativa, which includes industrial hemp and marijuana. Through our worldwide licensing agreement with FSL we are positioned to capitalize on the exploding demand for cannabinoid-based products and solutions. Currently, we remain focused on the American market where our hemp extracted cannabinoid products supplied by our strategic partner, Medropharm GmbH, are legal in all fifty states. And we will continue to monitor and position the company to capitalize on the evolving regulatory environment in Canada.”
In Canada, NSE will continue to support the Canadian Hemp Trade Alliance (CHTA) and its continued push for deregulation of industrial hemp and de-scheduling of hemp-derived cannabidiol (CBD). In recent months, the commercial market for hemp-derived CBD products has seen significant growth in the United States despite the fact that domestic hemp cultivation remains illegal in most states. Canada was scheduled to harvest over 100,000 acres of hemp in 2015 and continues to be a global leader in this sector. The Hemp Business Journal estimates that consumer sales of CBD-infused products are projected to reach $85M in 2015.
There are in excess of 80 cannabinoids within industrial hemp and marijuana, many being associated with health benefits. Two of the more recognizable cannabinoids are Tetrahydrocannabinol (THC) and cannabidiol (CBD). The technology from FSL allows us immediate access to commercial ready CBD products.
Cannabidiol (CBD), present in both industrial hemp and marijuana, is arguably becoming the most sought-after cannabis compound due to its medicinal and nutraceutical properties:
-Non-psychoactive?-Anticonvulsant?-Anti-epileptic?-Anti-inflammatory?-Antioxidant?-Antipsychotic?-Neurological protection
These new market segments offer NSE new revenue opportunities both from a licensing standpoint and direct retail sales.


Connect with Naturally Splendid (TSXV:NSP) to receive an Investor Kit.

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less